Q3 Asset Management’s Summit Therapeutics SMMT Stock Holding History

Q3 Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$337K	Hold	19,950	–	–	0.06%	58
2026 Q2	$290K	Hold	19,950	–	–	0.05%	66
2026 Q1	$378K	Buy	19,950 +383	+2%	+$6.19K	0.09%	60
2025 Q4	$342K	Hold	19,567	–	–	0.08%	57
2025 Q3	$404K	Hold	19,567	–	–	0.14%	46
2025 Q2	$416K	Buy	19,567 +3,094	+19%	+$70.6K	0.15%	39
2025 Q1	$317K	Hold	16,473	–	–	0.22%	41
2024 Q4	$293K	Hold	16,473	–	–	0.18%	45
2024 Q3	$360K	Buy	+16,473	New	+$230K	0.08%	42
2023 Q2	–	Sell	-15,761	Closed	-$27K	–	65
2023 Q1	$27K	Buy	+15,761	New	+$43K	0.02%	43

Other funds holding SMMT

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Hohimer Wealth Management Seattle, Washington $1.03B AUM 25.45% 1-Year Est. Return

Q3 Asset Management's SMMT Position: Q3 2026 in Review

Q3 Asset Management held its Summit Therapeutics (SMMT) position steady in Q3 2026 at 19,950 shares worth $337K. The position accounts for 0.06% of the portfolio, ranked #58.

Q3 Asset Management first reported a position in SMMT in Q1 2023 and has held it in 10 quarters since. The position peaked at $416K in Q2 2025. 147 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

Q3 Asset Management held 19,950 shares of Summit Therapeutics worth $337K as of Q3 2026.
Q3 Asset Management left its Summit Therapeutics share count unchanged in Q3 2026.
Summit Therapeutics made up 0.06% of Q3 Asset Management's portfolio in Q3 2026, its #58 holding.
Q3 Asset Management first reported a position in Summit Therapeutics in Q1 2023 and has held it in 10 quarters since.
Q3 Asset Management's Summit Therapeutics position peaked at $416K in Q2 2025.
147 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Q3 Asset Management's 13F filing for Q3 2026, filed 6 Nov 2026.